ClinicalTrials.gg
Active, not recruitingNCT03911505Updated Sep 17, 2026

ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD

A Phase 3 interventional study of Cipaglucosidase Alfa and Miglustat in Pompe Disease (Late-onset), sponsored by Amicus Therapeutics. Active, not recruiting at 17 sites in 6 countries. Open to participants aged 0 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Amicus Therapeutics (part of BioMarin Pharmaceutical) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
0 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies in Glycogen Storage Disease Type II by BioMarin Pharmaceutical — 2 open to participants now, 3 under way, 2 of them phase 3. Glycogen Storage Disease Type II · BioMarin Pharmaceutical.

Enrollment
8th of 10
21 · median 25
Started
2020
the only one that year
Phase 3
5 of 16
1 open now
Registered
12th of 16
by date

Among the 16 studies in Glycogen Storage Disease Type II by BioMarin Pharmaceutical, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2020, is one of 5 in phase 3, and was the 12th registered.

Glycogen Storage Disease Type II

162 studies on the registry are indexed under Glycogen Storage Disease Type II; 34 are open to participants now.

Browse Glycogen Storage Disease Type II studies →

Open to participants now

2 of the 16 studies in Glycogen Storage Disease Type II by BioMarin Pharmaceutical are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 23 Glycogen Storage Disease Type II studies recruiting now, 16 (70%) set no upper age limit and 6 (26%) stop at 75 or younger; 15 take children under 18; none take healthy volunteers.

This study: 0 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Glycogen Storage Disease Type II by BioMarin Pharmaceutical, or all of them as a file.
02

Study summary

This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treatment in enzyme replacement therapy (ERT)-experienced and ERT-naïve pediatric subjects with Pompe disease, aged 0 to \< 18 years

03

Conditions studied

  • Pompe Disease (Late-onset)

Keywords

  • Pompe
  • rhGAA
04

Who can participate

Ages eligible
0 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects (ERT-naïve [have never received a dose of rhGAA] or ERT-experienced [have received rhGAA every 2 weeks for at least 6 months immediately before enrollment, and if ERT dosage has been modified, must have been on the modified dosage for at least 3 months before enrollment]) diagnosed with LOPD who are aged 12 to \<18 years at screening (Cohort 1 only) or aged 0 months to \< 12 years at screening (Cohort 2 only)
  2. Subject weighs ≤ 115 kg. (Cohort 1 Only)
  3. Subject must have a diagnosis of LOPD based on documentation as defined in study protocol
  4. If of and if sexually active, female and male subjects agree to use a highly effective method of throughout the duration of the study and for up to 90 days after their last dose of Cipaglucosidase Alfa/Miglustat
  5. Subject has a sitting forced vital capacity (FVC) ≥ 30% of the predicted value for healthy Adolescents at screening (Cohort 1 only)
  6. Subject (aged 12 to \<18 years; Cohort 1) performs one 6-Minute Walk Test (6MWT) (≥ 75 meters) at screening that is valid, as determined by the clinical evaluator, or subject (aged ≥ 5 to \< 12 years; Cohort 2) performs one 6MWT (≥ 40 meters) at screening that is valid, as determined by the clinical evaluator

Exclusion criteria

Exclusion Criteria:

  1. Subject has received any /experimental drug, oral anabolic steroid or derivative, biologic, or device within 30 days or 5 half-lives of the therapy or treatment, whichever is longer, before screening
  2. Subject has received treatment with prohibited medications within 30 days of screening
  3. Subject has received any gene therapy at any time
  4. Subject has any intercurrent illness or condition at screening or baseline that may preclude the subject from fulfilling the protocol requirements or suggests to the investigator and/or the medical monitor that the potential subject may have an unacceptable risk by participating in this study
  5. Subject has a to any of the in ATB200, approved rhGAA, or AT2221
  6. Female subject is pregnant or breast-feeding at screening
  7. Subject requires the use of ventilation support for > 6 hours per day while awake
  8. Subject has evidence of moderate to severe hypertrophic cardiomyopathy aligning with classic IOPD
  9. In the opinion of the investigator, the parent or legally authorized representative is unlikely or unable to comply with the study requirements
  10. Subject has any prior history of illness or condition known to affect motor function, such as, but not limited to, Guillain-Barre syndrome, cerebral palsy, etc
  11. Subject who is diagnosed with Pompe disease via newborn screening and is asymptomatic (ie, showing no signs and symptoms of Pompe disease (Cohort 2 Only)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Cipaglucosidase Alfa (ATB200)/Miglustat(AT2221)

    Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat (AT2221) capsule

    Biological: Cipaglucosidase Alfa · Drug: Miglustat

Interventions

  • Enzyme Replacement Therapy via intravenous infusion

    Also known as: ATB200

  • Participants received Cipaglucosidase Alfa (ATB200) co-administered with Miglustat(AT2221)

    Also known as: AT2221

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs) from baseline

    Time frame: 52 weeks

Secondary outcomes

  1. Assessment of pharmacokinetic parameters

    ATB200 and AT2221 concentrations in plasma

    Time frame: 52 weeks

07

Study locations

17 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2020 (actual). Primary completion is estimated for Mar 2027, 85 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2019
First posted
Apr 11, 2019
StartActual
Feb 13, 2020
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03911505
Responsible party
Sponsor
First posted
Apr 11, 2019
Start date
Feb 13, 2020
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Sep 17, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cipaglucosidase alfa

Start the discussion